Form SC 13D/A DEPOMED INC Filed by: Starboard Value LP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Depomed (DEPO) Will Not Pursue Proposed Reincorporation
April 14, 2016 4:58 PM EDTDepomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company") today announced that it will not pursue the proposed reincorporation of the Company from California to Delaware that was proposed in its preliminary proxy statement for its upcoming Annual Meeting of Shareholders (the "Annual Meeting").... More
Janney Notes Strong Nucynta Rx Trends for March; Affirms DepoMed (DEPO) at 'Buy'
April 13, 2016 7:57 AM EDTJanney affirms DepoMed (Nasdaq: DEPO) at Buy with a fair value estimate of $28 following a check on recent prescription trends
Analyst Ken Trbovich noted that Nucynta ER prescription growth was 23 percent for March, which came in ahead of the firm's expectations. The analyst... More
